Johnson & Johnson outperforms expectations with robust 2024 results and 2025 outlook
Overview Johnson & Johnson (J&J) demonstrated solid financial performance in Q4 and full-year 2024, driven by strong results across its Innovative Medicine and MedTech segments, as well as a strategic focus on efficiency and innovation. Joaquin Duato, Chairman and Chief Executive Officer, placed a particularly important emphasis on the investments made by the company in…
